Effect of systemic treatment with N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-2-oxopiperidine-3- carboxamide (HIOC) or tauroursodeoxycholic Acid (TUDCA) on retinal ganglion cell death following optic nerve crush